AcelRx Pharmaceuticals, Inc. (ACRX) Bundle
A Brief History of AcelRx Pharmaceuticals, Inc. (ACRX)
Founding and Early Development
Founding and Early Development
AcelRx Pharmaceuticals, Inc. was founded in 2006 in Redwood City, California. The company focuses on the development of innovative therapies for the treatment of pain and has a strong emphasis on improving patient care through non-invasive delivery methods.
Initial Public Offering (IPO)
In 2013, AcelRx completed its initial public offering (IPO), raising approximately $35 million. The shares were offered at a price of $7.00 per share on the NASDAQ under the ticker symbol ACRX.
Product Pipeline and Development
The company's lead product candidate, DSUVIA (sufentanil sublingual tablet), was developed for the treatment of moderate to severe acute pain. In 2018, the U.S. Food and Drug Administration (FDA) approved DSUVIA, marking a significant milestone for AcelRx.
Financial Performance
As of the end of 2022, AcelRx reported total revenues of $3.2 million, primarily from product sales of DSUVIA. The company's net loss for the same year was $18.7 million.
In Q2 2023, AcelRx reported revenues of $1.5 million from DSUVIA sales. The company had cash and cash equivalents of approximately $3.8 million as of June 30, 2023.
Market Presence
AcelRx's product, DSUVIA, is indicated for use in medically supervised settings and is available in over 800 hospitals and healthcare facilities across the United States as of early 2023.
| Year | Revenue (in millions) | Net Loss (in millions) | Cash and Cash Equivalents (in millions) | DSUVIA Sales (in millions) |
|---|---|---|---|---|
| 2020 | 1.5 | 21.7 | 5.2 | 1.5 |
| 2021 | 2.1 | 13.2 | 7.1 | 0.9 |
| 2022 | 3.2 | 18.7 | 4.5 | 1.8 |
| 2023 (Q2) | 1.5 | 7.5 | 3.8 | 1.5 |
Recent Developments
In August 2023, AcelRx announced the completion of a financing round aimed at supporting ongoing sales and marketing efforts for DSUVIA. The total amount raised in this financing was $5 million.
Stock Performance
As of October 2023, AcelRx's stock price was approximately $0.80 per share, reflecting a market capitalization of around $40 million.
Future Outlook
AcelRx continues to explore opportunities for expanding the use of DSUVIA beyond acute pain management. The company is also evaluating potential partnerships to enhance its market presence and financial stability.
A Who Owns AcelRx Pharmaceuticals, Inc. (ACRX)
Current Ownership Structure
AcelRx Pharmaceuticals, Inc. (ACRX) has a diverse ownership structure comprising institutional investors, individual shareholders, and insiders. As of the latest available data, the ownership is distributed as follows:
| Ownership Type | Percentage of Total Shares | Number of Shares |
|---|---|---|
| Institutional Investors | 45.23% | 54,000,000 |
| Insider Ownership | 10.67% | 12,800,000 |
| Retail Investors | 44.10% | 52,500,000 |
Major Institutional Shareholders
Several institutional investors play a significant role in AcelRx's ownership. Key institutional shareholders include:
| Institutional Investor | Shares Owned | Percentage of Ownership |
|---|---|---|
| BlackRock, Inc. | 7,500,000 | 6.24% |
| The Vanguard Group, Inc. | 6,800,000 | 5.67% |
| Wellington Management Company LLP | 5,300,000 | 4.41% |
| State Street Corporation | 4,900,000 | 4.06% |
| Renaissance Technologies LLC | 3,600,000 | 3.00% |
Insider Ownership
Insider ownership is crucial for aligning management interests with those of shareholders. The following individuals hold significant shares:
| Insider Name | Title | Shares Owned |
|---|---|---|
| Vincent M. Angotti | CEO | 2,000,000 |
| Michael E. Gurry | CFO | 1,500,000 |
| Mark A. L. Wiggins | Board Member | 1,000,000 |
| John T. Tilley | Board Member | 800,000 |
Recent Financial Performance
AcelRx Pharmaceuticals has seen fluctuations in its stock performance and financial metrics. Recent statistics include:
| Financial Metric | Value |
|---|---|
| Market Capitalization | $80 million |
| Latest Stock Price | $1.10 |
| Annual Revenue (Last Reported) | $10 million |
| Net Loss (Last Reported) | -$20 million |
Recent Shareholder Changes
Recent changes in shareholder composition have been observed, particularly with institutional investors increasing their stakes. The following events were notable:
- Increased holdings by BlackRock, Inc. by 1.5 million shares in Q2 2023.
- Vanguard adjusted its position, adding 500,000 shares in the last quarter.
- Several insiders sold shares totaling approximately 400,000 shares at the end of 2023.
Future Outlook
With ongoing developments in product pipelines and clinical trials, the ownership dynamics may shift. Investors are especially focused on:
- Upcoming FDA approvals for new drugs in 2024.
- Potential partnerships or acquisitions that could change the financial landscape.
- The impact of market trends on stock performance and ownership percentages.
AcelRx Pharmaceuticals, Inc. (ACRX) Mission Statement
Corporate Vision
Corporate Vision
AcelRx Pharmaceuticals, Inc. focuses on the management of pain through innovative therapies, primarily targeting patients experiencing acute and chronic pain. The company's mission is to develop novel therapies aimed at enhancing the quality of life for patients while providing healthcare professionals with effective tools to manage pain.
Strategic Objectives
- Leverage scientific expertise to develop innovative product candidates.
- Conduct comprehensive clinical trials to validate the safety and efficacy of their products.
- Establish partnerships with healthcare providers and institutions to improve patient outcomes.
- Ensure regulatory compliance and streamline the approval process for innovative pain management solutions.
Financial Overview
The financial performance of AcelRx Pharmaceuticals evidences its growth potential within the biopharmaceutical industry. As of the end of Q3 2023, AcelRx reported:
| Financial Metric | Value |
|---|---|
| Revenue (Q3 2023) | $5.1 million |
| Net Loss (Q3 2023) | ($2.3 million) |
| Total Assets (Q3 2023) | $38.2 million |
| Current Liabilities (Q3 2023) | $3.4 million |
| Cash and Cash Equivalents (Q3 2023) | $30.6 million |
Product Pipeline
AcelRx's commitment to innovation is reflected in its diversified pipeline, which includes the following key products:
| Product | Indication | Development Stage |
|---|---|---|
| DSUVIA | Acute pain management | Market Approved |
| ARX-04 | Post-operative pain | Phase 3 Clinical Trial |
| ARX-03 | Chronic pain | Pre-Clinical |
Market Position
AcelRx Pharmaceuticals operates in the global pain management market, which is projected to reach approximately $59 billion by 2027. The company aims to capture market share through its targeted therapies and partnerships, focusing on both acute and chronic pain management sectors.
Conclusion of Mission Commitment
In essence, AcelRx Pharmaceuticals remains dedicated to its mission of revolutionizing pain management by fostering innovation, ensuring patient safety, and enhancing treatment efficacy through its advanced therapies and robust clinical studies.
How AcelRx Pharmaceuticals, Inc. (ACRX) Works
Overview of AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of pain. The company’s flagship product is DSUVIA, a sublingual formulation of sufentanil, which is designed for use in medically supervised settings.
Business Model
AcelRx's business model revolves around developing, manufacturing, and marketing prescription medications that address unmet medical needs in pain management. The company partners with healthcare providers and institutions to ensure the effective distribution of its products.
Product Pipeline
| Product | Indication | Status | Launch Date |
|---|---|---|---|
| DSUVIA | Acute Pain | Approved | December 2018 |
| ARX-04 | Post-operative Pain | Phase 3 Trials | Expected Q4 2023 |
| ARX-02 | Chronic Pain | Preclinical | N/A |
Financial Performance
As of Q2 2023, AcelRx reported financial results indicating a revenue of $1.2 million, primarily from DSUVIA sales. The net income for the same period was reported as - $2.5 million.
For the fiscal year ended 2022, AcelRx's total revenue was $3 million, with an operating loss of $10.4 million. As of June 30, 2023, the company had cash and cash equivalents totaling $25.5 million.
Market Performance
In October 2023, AcelRx's stock traded at approximately $0.57 per share, with a market capitalization of around $27 million. The stock has seen a 52-week range from $0.36 to $1.12.
Key Partnerships and Collaborations
- Partnership with Navidea Biopharmaceuticals for the development of ARX-04.
- Collaboration with medical institutions for conducting clinical trials.
- Agreements with pharmaceutical distributors for product supply and marketing.
Regulatory Environment
AcelRx operates in a highly regulated environment where it must comply with the requirements set by the U.S. Food and Drug Administration (FDA). Its products undergo rigorous testing and approval processes, which are crucial for market entry and sustainability.
Risks and Challenges
- Competition from other pain management products and technologies.
- Regulatory hurdles that can delay product approval.
- Market acceptance of new products within the healthcare community.
Conclusion of Operations
The operational framework of AcelRx Pharmaceuticals, Inc. is characterized by its focus on innovation within the pain management market, leveraging strategic partnerships, and navigating the complex regulatory landscape to bring its products to market.
How AcelRx Pharmaceuticals, Inc. (ACRX) Makes Money
Revenue Streams
AcelRx Pharmaceuticals primarily generates revenue through the commercialization of its proprietary products, particularly focusing on pain management therapies. The main product in their portfolio includes:
- DSUVIA - Approved by the FDA for the management of moderate to severe acute pain.
As of the latest financial reports, AcelRx reported that DSUVIA achieved $9.1 million in net product sales for the year ended December 31, 2022.
Partnerships and Licensing Agreements
AcelRx leverages partnerships and licensing agreements to expand their market reach and enhance revenue potential. Some notable agreements include:
- Distribution Agreement with Alvogen - A collaboration focused on the commercialization of DSUVIA in the U.S.
- International Licensing Deals - Engaging in agreements with companies for the distribution of their products in foreign markets.
Financial Performance Overview
| Year | Net Product Sales | Operating Expenses | Net Loss |
|---|---|---|---|
| 2020 | $4.0 million | $26.2 million | $22.3 million |
| 2021 | $6.3 million | $25.5 million | $20.1 million |
| 2022 | $9.1 million | $22.1 million | $13.0 million |
Research and Development (R&D) Investments
AcelRx continuously invests in R&D to cultivate a pipeline of new products, which is critical for long-term revenue generation. For 2022, the company allocated $15.9 million to R&D activities, focusing on:
- Advancing clinical trials for additional indications of DSUVIA
- Exploring new product candidates for pain management
Market Strategy and Commercialization
The commercialization strategy includes direct-to-hospital sales, engagement with healthcare professionals, and participation in medical conferences. AcelRx aims to enhance penetration in the surgical and emergency care settings through targeted marketing efforts.
Cost Structure Analysis
The cost structure of AcelRx consists primarily of:
- Manufacturing Costs - Associated with the production of DSUVIA.
- Sales and Marketing Expenses - Essential for promoting their products.
- General and Administrative Expenses - Covering operational aspects of the business.
In 2022, the breakdown of operating expenses was as follows:
| Expense Category | Amount (in million $) |
|---|---|
| Manufacturing Costs | $5.0 million |
| Sales and Marketing | $10.0 million |
| General and Administrative | $7.1 million |
AcelRx Pharmaceuticals, Inc. (ACRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support